



COPY OF PAPERS
ORIGINALLY FILED

1642

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on July 18, 2002

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

ELECTION UNDER 35 USC § 121

Examining Group 1642

Patent Application

Docket No. GJE-59

Serial No. 09/786,015

#11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Stephen L. Rawlings, Ph.D.
Art Unit : 1642
Applicants : Peter Harrison
Serial No. : 09/786,015
Conf. No. : 6391
Filed : February 28, 2001
For : High-Affinity Antibodies

RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

7-2002

Assistant Commissioner for Patents
Washington, D.C. 20231

ELECTION UNDER 35 USC §121

Sir:

In response to the written restriction requirement dated June 2, 2002, the Applicant hereby
elects, to prosecute the Group I claims, i.e. claims 1-8 drawn to an antibody.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as
required by this paper to Deposit Account 19-0065.

Respectfully submitted,

David R. Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address : 2421 N.W. 41st Street

Suite A-1

Gainesville, FL 32606

DRS/la

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231, on July 19, 2001

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

AMENDMENT UNDER
37 CFR §1.825(a) THROUGH (c)
Examining Group 1642
Patent Application
Docket No. GJE-59
Serial No. 09/786,015

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Unit : 1642
Applicants : Peter Harrison
Serial No. : 09/786,015
Filed : February 28, 2001
For : High-Affinity Antibodies

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825:

In the Specification

Please replace pages 1-4 (Sequence Listing) with new pages 1-4 attached hereto.

Remarks

This amendment is made to conform the application with the provisions of 37 CFR §§1.821 through 1.825. I hereby certify that no new material is being added by this submission.

RECEIVED
JUL 26 2001
TECH CENTER 1600/2900

#17/18
7/27/01
R/S

